209 related articles for article (PubMed ID: 34840210)
1. Current Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features.
Tonooka A; Ohashi R
J Nippon Med Sch; 2022 May; 89(2):128-138. PubMed ID: 34840210
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
3. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
4. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
Pfister F; Amann K; Daniel C; Klewer M; Büttner A; Büttner-Herold M
Histopathology; 2018 Dec; 73(6):990-1001. PubMed ID: 30014486
[TBL] [Abstract][Full Text] [Related]
5. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
Saeed A; Park R; Sun W
J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
[TBL] [Abstract][Full Text] [Related]
6. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
7. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.
Ozawa M; Ohtani H; Komatsuda A; Wakui H; Takahashi N
Clin Exp Nephrol; 2021 Nov; 25(11):1193-1202. PubMed ID: 34115234
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab-associated glomerular microangiopathy.
Person F; Rinschen MM; Brix SR; Wulf S; Noriega MLM; Fehrle W; Schmitz J; Schwarz A; Ivanyi P; Steinmetz OM; Reinhard L; Hoxha E; Zipfel PF; Bräsen JH; Wiech T
Mod Pathol; 2019 May; 32(5):684-700. PubMed ID: 30552416
[TBL] [Abstract][Full Text] [Related]
9. Renal Toxicities of Targeted Therapies.
Abbas A; Mirza MM; Ganti AK; Tendulkar K
Target Oncol; 2015 Dec; 10(4):487-99. PubMed ID: 25922090
[TBL] [Abstract][Full Text] [Related]
10. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.
Gao F; Yang C
Curr Cancer Drug Targets; 2020; 20(1):3-18. PubMed ID: 31729943
[TBL] [Abstract][Full Text] [Related]
11. Association of thrombotic microangiopathy with atezolizumab therapy in cancer patients.
Izzedine H; Mathian A; Albiges L; Champiat S; Brocheriou I
Eur J Cancer; 2021 May; 149():34-36. PubMed ID: 33819719
[No Abstract] [Full Text] [Related]
12. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
Cortazar FB; Marrone KA; Troxell ML; Ralto KM; Hoenig MP; Brahmer JR; Le DT; Lipson EJ; Glezerman IG; Wolchok J; Cornell LD; Feldman P; Stokes MB; Zapata SA; Hodi FS; Ott PA; Yamashita M; Leaf DE
Kidney Int; 2016 Sep; 90(3):638-47. PubMed ID: 27282937
[TBL] [Abstract][Full Text] [Related]
13. Adverse events of targeted anticancer therapies: what radiologists need to know.
López Sala P; Alberdi Aldasoro N; Unzué García-Falces G
Radiologia (Engl Ed); 2020; 62(3):229-242. PubMed ID: 32057481
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
16. [Renal Side Effects of Novel Molecular Targeted Oncologic Agents].
Fenoglio R; Cortazzi S; Marchisio M; Rabajoli G; Terzolo E; Sciascia S; Roccatello D
G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007829
[TBL] [Abstract][Full Text] [Related]
17. Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Yılmaz S; Özçakar ZB; Taktak A; Kiremitçi S; Ensari A; Dinçaslan H; Yalçınkaya F
Pediatr Nephrol; 2016 Jun; 31(6):1029-32. PubMed ID: 26928310
[TBL] [Abstract][Full Text] [Related]
18. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
[No Abstract] [Full Text] [Related]
19. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
20. Renal thrombotic microangiopathy during nintedanib treatment for idiopathic pulmonary fibrosis
.
Inoue D; Nishi H; Honda K; Ishii T; Abe H; Sato M; Nangaku M
Clin Nephrol; 2020 Jan; 93(1):47-50. PubMed ID: 31699213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
